13F Holdings
中文EN

ALT Altimmune, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1326190 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY105.0%
TTM net income YoY7.3%
TTM EPS YoY25.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-230,461.0%
Net margin-214,861.0%
FCF margin—
EBITDA margin-230,187.8%

Returns

ROE-50.6%
ROA-42.0%
ROIC (approx.)-49.4%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets19.7%
Debt / equity0.15x
Current ratio18.55x
Interest coverage-57.76x

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio-9.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$41,000$20,000$426,000-$68,000$4.41M
R&D expense$66.43M$82.23M$65.80M$70.54M$74.54M
SG&A expense$28.10M$20.97M$18.14M$17.13M$15.41M
Operating income-$94.49M-$103.17M-$95.93M-$87.74M-$96.91M
Interest expense$1.64M$9,000$35,000$8,000$5,000
Pretax income-$88.77M-$95.06M-$88.45M-$84.91M-$97.09M
Income tax-$681,000——-$197,000—
Net income-$88.09M-$95.06M-$88.45M-$84.71M-$97.09M
EBITDA-$94.38M-$102.93M-$95.45M-$87.25M-$96.36M
EPS (basic)-1.00-1.34-1.66-1.81-2.35
EPS (diluted)-1.00-1.34-1.66-1.81-2.35
Weighted avg. shares (diluted)88.10M71.00M53.25M46.93M41.28M
Balance sheet
Cash & equivalents$43.76M$36.97M$135.16M$111.13M$190.34M
Short-term investments$229.70M$94.97M$62.70M$73.78M—
Current assets$278.19M$137.25M$209.63M$192.81M$204.13M
PP&E, net$312,000$413,000$651,000$1.08M$1.45M
Intangibles—$0$0$12.42M$12.42M
Total assets$279.93M$139.31M$210.64M$206.93M$218.87M
Current liabilities$15.00M$10.47M$12.14M$17.05M$18.28M
Long-term debt$34.29M——$4.58M$1.45M
Total debt$34.29M——$4.58M$1.45M
Total liabilities$55.04M$15.80M$16.54M$21.64M$19.73M
Shareholders' equity$224.89M$123.51M$194.10M$185.29M$199.13M
Net debt-$9.47M——-$106.55M-$188.88M
Shares outstanding110.88M72.35M70.68M49.20M40.99M
Cash flow statement
Operating cash flow-$67.53M-$79.85M-$75.81M-$62.59M-$78.24M
Capital expenditure$11,000—$47,000$126,000$12.12M
Free cash flow-$67.55M—-$75.86M-$62.71M-$90.36M
Investing cash flow-$132.47M-$28.39M$13.73M-$73.40M$87.52M
Financing cash flow$206.84M$10.04M$86.11M$56.78M$65.10M
Depreciation & amortization$112,000$238,000$477,000$493,000$551,000
Stock-based compensation$16.08M$14.39M$10.64M$8.10M$5.52M

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.